WARFARIN Drug Interactions
Also known as: Warfarin Sodium
Warfarin is a "blood thinner" (anticoagulant) medication that helps prevent harmful blood clots from forming or growing larger in your body. It is prescribed to reduce the risk of serious problems like strokes, heart attacks, and clots in the legs or lungs, especially for people with certain heart conditions or after a heart attack.WARFARIN has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Taking naproxen with warfarin significantly increases your risk of serious bleeding, including stomach bleeding. This combination should generally be avoided.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Warfarin, an anticoagulant, inhibits vitamin K-dependent clotting factors. The combined effect is a synergistic impairment of hemostasis, increasing the risk of bleeding.
Clinical Management
This interaction can lead to severe bleeding complications, including gastrointestinal bleeding, intracranial hemorrhage, and other forms of internal bleeding. The risk of major gastrointestinal bleeding can be 3 to 15 times higher when NSAIDs are combined with warfarin. This combination is generally not recommended. If an NSAID is absolutely necessary, consider alternative pain relief options or a COX-2 selective inhibitor with caution and close monitoring. If co-administration is unavoidable, monitor INR frequently, educate the patient on bleeding signs, and consider gastroprotective agents. The lowest effective doses for the shortest duration should be used.
Combining etodolac with warfarin significantly increases your risk of serious bleeding, including stomach bleeding, which can be life-threatening. It is generally recommended to avoid this combination.
Mechanism
Etodolac, an NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis, which impairs gastric mucosal protection and platelet aggregation. Warfarin, an anticoagulant, inhibits vitamin K-dependent clotting factors. The combined effect leads to an additive antiplatelet effect and increased gastrointestinal toxicity, significantly elevating bleeding risk.
Clinical Management
This interaction can lead to severe and potentially fatal bleeding, particularly gastrointestinal bleeding, which may manifest as black, tarry stools or vomiting blood. The risk of major gastrointestinal bleeding is increased 3 to 15 times compared to warfarin alone. Other bleeding events like bruising, nosebleeds, or hematuria may also occur. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID (like celecoxib) with extreme caution and close monitoring, though even COX-2 inhibitors carry risk. If co-administration is unavoidable, monitor INR frequently, educate the patient on bleeding signs, and consider gastroprotective agents. Proton pump inhibitors are often recommended for gastroprotection.
Combining aspirin with warfarin significantly increases your risk of serious bleeding, including stomach bleeding, which can be life-threatening. Avoid this combination unless specifically directed and closely monitored by your doctor.
Mechanism
Aspirin inhibits platelet aggregation and can cause gastric irritation, while warfarin inhibits vitamin K-dependent clotting factors. The concurrent use leads to a synergistic anticoagulant effect, impairing both primary hemostasis (platelet plug formation) and secondary hemostasis (clotting cascade). This combined effect drastically elevates the risk of hemorrhage.
Clinical Management
Patients taking both aspirin and warfarin have a substantially increased risk of gastrointestinal bleeding (3-15 times higher), intracranial hemorrhage, and other major bleeding events. This interaction can also lead to an elevated International Normalized Ratio (INR), indicating excessive anticoagulation. Bleeding can range from bruising and nosebleeds to severe, life-threatening internal hemorrhages. This combination should generally be avoided due to the high risk of major bleeding. If co-administration is deemed absolutely necessary (e.g., for specific cardiac conditions), it must be under strict medical supervision with frequent INR monitoring and close observation for any signs of bleeding. Proton pump inhibitors may be considered to reduce gastrointestinal bleeding risk, and alternative antiplatelet or anticoagulant therapies should be explored.
Taking ibuprofen with warfarin significantly increases your risk of serious bleeding, especially from the stomach or intestines. It is generally advised to avoid this combination due to the heightened danger.
Mechanism
Ibuprofen, a non-steroidal anti-inflammatory drug (NSAID), inhibits platelet aggregation and can cause direct irritation and damage to the gastrointestinal lining. Warfarin, an anticoagulant, reduces the production of clotting factors. The combined effect leads to a synergistic increase in bleeding risk.
Clinical Management
This interaction can lead to severe bleeding complications, including gastrointestinal hemorrhage, intracranial hemorrhage, and other internal bleeding, which can be life-threatening. The risk of major gastrointestinal bleeding is estimated to be 3-15 times higher when NSAIDs are co-administered with warfarin. This combination should generally be avoided. If pain relief is necessary, consider acetaminophen as a safer alternative. If NSAID use is unavoidable, use the lowest effective dose for the shortest duration, and monitor INR more frequently for potential elevation. Patients should be educated on signs of bleeding and seek immediate medical attention if they occur.
Combining indomethacin with warfarin significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely avoid this combination or monitor you very closely.
Mechanism
Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis. This leads to impaired platelet aggregation and can cause gastric mucosal damage, increasing the risk of gastrointestinal bleeding. Warfarin is an anticoagulant that inhibits vitamin K-dependent clotting factors, leading to a reduced clotting ability. The concurrent use of these drugs results in additive antiplatelet and anticoagulant effects, alongside increased GI mucosal vulnerability.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or fatal. Studies indicate a 3-15 times higher risk of serious GI bleeding when NSAIDs are co-administered with warfarin. Other bleeding manifestations like epistaxis, hematuria, and ecchymosis may also occur, along with potential for increased INR. This combination should generally be avoided due to the high risk of serious bleeding. If concurrent use is unavoidable, patients require extremely close monitoring of INR, signs of bleeding (e.g., melena, hematemesis, unusual bruising), and hemoglobin levels. Lower doses of indomethacin for the shortest possible duration may be considered, but alternative analgesics or anti-inflammatory agents with less bleeding risk (e.g., acetaminophen, selective COX-2 inhibitors with caution) should be preferred.
Taking celecoxib with warfarin significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor or pharmacist will likely advise against using these medications together.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal protection and platelet aggregation. Warfarin, an anticoagulant, inhibits vitamin K-dependent clotting factors. The combination leads to an additive antiplatelet effect and increased gastrointestinal mucosal damage, potentiating the risk of hemorrhage.
Clinical Management
The primary clinical effect is a significantly increased risk of bleeding, particularly gastrointestinal bleeding, which can be life-threatening. Studies show that concurrent use of NSAIDs with warfarin can increase the risk of serious GI bleeding by 3 to 15 times compared to warfarin alone. Other bleeding sites, such as intracranial hemorrhage, can also be elevated. Concurrent use of celecoxib and warfarin should generally be avoided due to the high risk of severe bleeding. If an NSAID is absolutely necessary, consider alternatives with lower GI risk or shorter half-lives, and monitor INR very closely. Proton pump inhibitors should be co-prescribed to reduce GI bleeding risk if the combination is unavoidable. Consider non-pharmacological pain management or non-NSAID analgesics.
Combining piroxicam with warfarin significantly increases your risk of bleeding, including serious internal bleeding. Your doctor will likely avoid this combination due to the high risk.
Mechanism
Piroxicam, a non-selective NSAID, inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis. This leads to decreased platelet aggregation and can cause gastrointestinal mucosal damage. Warfarin is an anticoagulant that inhibits vitamin K-dependent clotting factors. The concurrent use results in an additive antiplatelet effect and impaired coagulation, exacerbated by potential GI irritation from the NSAID.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be life-threatening. Studies show a 3- to 15-fold increase in GI bleeding risk when NSAIDs are combined with warfarin. Other bleeding manifestations include epistaxis, hematuria, and intracranial hemorrhage. This combination should generally be avoided. If an NSAID is absolutely necessary for a patient on warfarin, consider alternative analgesics or a short course of a COX-2 selective NSAID with extreme caution, close INR monitoring, and vigilant observation for bleeding signs. Proton pump inhibitors should be co-prescribed to reduce GI bleeding risk. Topical NSAIDs may be a safer alternative for localized pain.
Combining meloxicam with warfarin significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor may need to adjust your medications or monitor you very closely.
Mechanism
Meloxicam, an NSAID, inhibits prostaglandin synthesis, which can impair platelet function and damage the gastrointestinal mucosa. Warfarin, an anticoagulant, inhibits vitamin K-dependent clotting factors. The combination leads to additive antiplatelet effects and increased anticoagulant activity, significantly elevating bleeding risk.
Clinical Management
This interaction can lead to severe bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, and other internal bleeding. The risk of major GI bleeding is estimated to be 3 to 15 times higher when NSAIDs are co-administered with warfarin compared to warfarin alone. Avoid concurrent use of meloxicam and warfarin if possible. If co-administration is unavoidable, closely monitor INR and signs of bleeding (e.g., black/tarry stools, unusual bruising). Consider alternative pain management strategies or a gastroprotective agent (e.g., PPI) if NSAID use is essential. Discuss with your physician for alternative pain relief.
Taking diclofenac, an anti-inflammatory pain reliever, with warfarin, a blood thinner, significantly increases your risk of serious bleeding, including stomach bleeding. Your doctor will likely recommend avoiding this combination.
Mechanism
Diclofenac inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis, which impairs platelet function and can damage the gastrointestinal mucosa. Warfarin works by blocking vitamin K-dependent clotting factors, leading to a decreased ability of blood to clot. The combination results in additive antiplatelet effects and increased gastrointestinal toxicity, potentiating the anticoagulant effect of warfarin.
Clinical Management
This combination significantly increases the risk of major bleeding, especially gastrointestinal bleeding, which can be life-threatening. The risk of GI bleeding is estimated to be 3 to 15 times higher when NSAIDs are co-administered with warfarin. Other potential effects include increased bruising, nosebleeds, and hematuria. This combination should generally be avoided. If an NSAID is absolutely necessary, a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk, and the patient's INR should be monitored very closely and frequently. Alternatives to NSAIDs for pain, such as acetaminophen or opioids, should be considered. If unavoidable, use the lowest effective dose for the shortest duration possible.
Combining ketorolac with warfarin significantly increases your risk of bleeding, including serious and life-threatening internal bleeding. This combination should generally be avoided.
Mechanism
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Warfarin is an anticoagulant that inhibits vitamin K-dependent clotting factors. The concurrent use of these agents results in additive antiplatelet and anticoagulant effects, profoundly increasing the risk of hemorrhage.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or fatal. Studies indicate that the risk of major gastrointestinal bleeding is 3 to 15 times higher when NSAIDs are co-administered with warfarin. Other potential bleeding sites include intracranial, genitourinary, and soft tissue. This combination is generally contraindicated due to the high risk of severe bleeding. If concurrent use is unavoidable, extreme caution, close monitoring of INR and signs of bleeding, and the lowest effective dose of ketorolac for the shortest duration are essential. Consider alternative pain management strategies that do not increase bleeding risk, such as acetaminophen or opioids, if appropriate.
For complete prescribing information:
View full WARFARIN monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.